The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA®</ ...

Cite this: Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors - Medscape - Aug 01, 2011.

Table 1. Summary of medical therapy (chemotherapy and aromatase inhibitors) and measurements of cognitive functioning (neuropsychological testing and functional imaging) and potential confounders ...

In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

Virtual design and prediction of single- or multitarget inhibitors of cancer-related proteins, including aromatase is also a hot topic. (20) A molecule able to simultaneously inhibit many different ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...